PPD appoints Bruce Stouffer as immunochemistry head
Pharmaceutical Product Development (PPD) has announced that Bruce Stouffer has joined PPD as executive director of immunochemistry in the PPD Laboratories’ bioanalytical lab.
“Bruce brings extensive experience and strong leadership skills to our talented immunochemistry team,” said David Johnston, Ph.D., executive vice president of global laboratory services for PPD. “As a recognized industry leader, Bruce is an exceptional asset for our clients’ research programs.”
Stouffer previously served as director of analytical and bioanalytical development for Bristol-Myers Squibb, where he managed a group of scientists with responsibilities including contract operations, quality control, and small and large molecule bioanalytical project management. Previously, Stouffer was responsible for the bioanalytical sciences late-phase group, responsible for management of post-phase II bioanalysis, as well as support for new chemical entity (NCE) filings.
Stouffer spent the early part of his research career in biomedical sciences as a technologist and lab supervisor at Roche Biomedical Labs. In 1982, he joined the Squibb Institute for Biomedical Research, developing immunoassays to support numerous small and large molecule programs for Bristol-Myers Squibb.
PPD Laboratories’ bioanalytical labs, located in Richmond, Virginia, and Middleton, Wisconsin, provide accurate and timely bioanalysis in a good laboratory practice (GLP)-compliant setting to advance small molecule and biologics development from preclinical studies through all phases of clinical trials. PPD’s immunochemistry scientists have contributed to the development of accepted industry methods for immunochemistry and are continually developing, validating and transferring new, industry-leading methods to the bioanalytical laboratory.